Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-10-25
2005-10-25
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S048000, C514S262100, C514S266400, C514S449000
Reexamination Certificate
active
06958324
ABSTRACT:
Inosine compounds, compositions comprising an inosine compound and methods for treating or preventing an inflammation disease or a reperfusion disease comprising administering an effective amount of an inosine compound to a patient in need thereof are disclosed.
REFERENCES:
patent: 3407190 (1968-10-01), Honjo et al.
patent: 4459292 (1984-07-01), Andermann et al.
patent: 4870002 (1989-09-01), Kiel
patent: 5234922 (1993-08-01), Welsh et al.
patent: 5260275 (1993-11-01), Cooper et al.
patent: 5614504 (1997-03-01), Hadden et al.
patent: 5856360 (1999-01-01), Salzman et al.
patent: 5922769 (1999-07-01), Barelli et al.
patent: 6060459 (2000-05-01), von Borstel et al.
patent: 6150383 (2000-11-01), Ikeda et al.
patent: 6342484 (2002-01-01), Kulkarni et al.
patent: 0688766 (1995-12-01), None
patent: 0749751 (1996-12-01), None
patent: 1153931 (2001-11-01), None
patent: 53-044471 (1978-11-01), None
patent: 6610578 (1967-01-01), None
patent: 214899 (2000-05-01), None
patent: 215336 (2000-07-01), None
patent: 2160591 (2000-12-01), None
patent: WO 90/09792 (1990-09-01), None
patent: WO 96/09823 (1996-04-01), None
patent: WO 96/33203 (1996-10-01), None
patent: WO 97/17975 (1997-05-01), None
patent: WO 98/56378 (1998-12-01), None
patent: WO 99/18932 (1999-04-01), None
patent: WO 99/37151 (1999-07-01), None
patent: WO 00/47601 (2000-08-01), None
Almawi et al., 1999, “Clinical review 103: T helper type 1 and 2 cytokines mediate the onset and progression of type I (insulin-dependent) diabetes”, J. Clin. Endocrinol. Metab. 84:1497-1502.
Bankers-Fulbright et al., 1998, “Sulfonylureas inhibit cytokine-induced eosinophil survival and activation”, J. Immunol. 160-5546-5553.
Dielman et al., 1997, “Role of animal models for the pathogenesis and treatment of inflammatory bowel disease”; Scand. J. Gastroenterol. Suppl. 223:99-104.
Dunning, 1999, “Nateglinide; a glucose-sensitive insulinotropic agent that is chemically and pharmacologically distinct from the sulfonylureas”, Curr. Opin. Endocrinol. Diabetes 6(suppl. 1):S29-S31.
Gaudio et al., 1999, “Dextran sulfate sodium (DSS) colitis in rats: clinical, structural, and ultrastructural aspects”, Dig. Dis. Sci. 44:1458-1475.
Green, 1981,Protective Groups in Organic Synthesis, John Wiley & Sons, (table of contents).
Hasko et al., 2000, “Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock”, J. Immunol. 164:1013-1019.
Hasko et al., 1999, “Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock”, J. Am. Soc. Hematol. 94:427a (abstract No. 1893).
Jurkowitz et al., 1998, “Adenosine, inosine and guanosine protect glial cells during glucose deprivation and mitochondrial inhibition: correlation between protection and ATP preservation”, J. Neurochem. 71:535-548.
Kimura et al., “Determination of the active molety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats”, Arzneimittelforschung 48:1091-1096.
Kipshidze et al., 1983, “Inosine effect on high-energy phosphate content, mechanical activity of glycerinated fiber bundles, morphology and microcirculation in myocardium in toxi-allergic myocarditis”, Methods Find. Exp. Clin. Pharmacol. 5:163-170.
Kolb et al., 1987, “Analysis of 22 immunomodulatory substances for efficacy in low-dose streptozotocin-induced diabetes”, Diabetes Res. 6:21-27.
Kuninaka et al., 1980, “Flavor activity of sulfur-containing compounds related to flavor nucleotides”, Agric. Biol. Chem. 44:1437-1439.
March, 1992, in:Advanced Organic Chemistry, Reaction Mechanisms and Structure4thed., John Wiley& Sons, pp. 404-408.
Murthy et al., 1999, “Combination therapy of pentoxifylline and TNFα monoclonal antibody in dextran sulphate-induced mouse colitis”, Ailment Pharmacol Ther.13:251-260.
Norton et al., 2001, “Use of nucleotides in weanling rats with diarrhea induced by a lactose overload: effect on the evolution of diarrhea and weight and on the histopathology of intestine, liver and spleen”, Braz. J. Med. Biol. Res. 34:195-202.
Perfetti et al., 1998, “Novel therapeutic strategies for the treatment of type 2 diabetes”, Diabetes Metab. Rev. 14:207-225.
Qiu et al., 2000, “IMP and AMP deaminase in reperfusion injury down-regulates neutrophil recruitment”, Proc. Natl. Acad. Sci. USA 97:4267-4272.
Rabinovitch et al., 1998, “Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus”, Biochem. Pharmacol. 55:1139-1149.
Sasaki et al., 2000, “Prostaglandin E2 inhibits lesion formation in dextran sodium sulphate-induced colitis in rats and reduces the levels of mucosal inflammatory cytokines”, Scand. J. Immunol. 51:23-28.
Szabo et al., 1998, “Supression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists”, Brit. J. Pharm. 125-397-398.
Veerabagu et al., 1996, “Intravenous nucleosides and a nucleotide promote healing of small bowel ulcers in experimental enterocolitis”, Dig. Dis. Sci. 41:1452-1457.
Wada et al., 2001, “Inosine monophoshate and aspirin-triggered 15-epi-lipoxin A4 act in concert to regulate neutrophil trafficking: additive actions of two new endogenous anti-inflammatory mediators”, J. Hematother. Stem Cell Res, 10:75-79.
Salzman Andrew L.
Szabo Csaba
Inotek Pharmaceuticals Corporation
Kim Jennifer
Wang Shengjun
Wilmer Cutler Pickerinf Hale and Dorr LLP
LandOfFree
Inosine compounds and their use for treating or preventing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inosine compounds and their use for treating or preventing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inosine compounds and their use for treating or preventing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3472417